Latest Pharma Insights
Uniquity’s Phase II Solrikitug Data In EoE Rival Amgen/AstraZeneca’s Tezspire
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
US Proposal Allowing NAC Use In Supplements Frames Door Through ‘Preclusion Clause’ For More
Proposed rule notes regulatory emphasis on protecting incentives for new drug development but suggests FDA could consider requests for exceptions to prohibition on using in supplements ingredients previously studied or approved for use as drugs.
HBW Insight - November 17, 2026
Proposed rule notes regulatory emphasis on protecting incentives for new drug development but suggests FDA could consider requests for exceptions to prohibition on using in supplements ingredients previously studied or approved for use as drugs.
HBW Insight - November 17, 2026
Uniquity’s Phase II Solrikitug Data In EoE Rival Amgen/AstraZeneca’s Tezspire
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
‘Era Of Super Intelligence’ Comes To FDA Documents; Sponsors Can Still Say AI
To comply with an executive order, the FDA will begin using “super intelligence” instead of artificial intelligence in new documents and communications going forward, and eventually will update all forms and templates with the revised term.
Medtech Insight - November 16, 2026
To comply with an executive order, the FDA will begin using “super intelligence” instead of artificial intelligence in new documents and communications going forward, and eventually will update all forms and templates with the revised term.
Medtech Insight - November 16, 2026
Medtech Regulators Push For Whole-Lifecycle Monitoring In 2027
Regulators across the world are moving from one-time approvals to continuous lifecycle monitoring, but most medtech manufacturers lack the systems and internal alignment to keep up, said speakers at the Veeva MedTech Summit.
Medtech Insight - November 16, 2026
Regulators across the world are moving from one-time approvals to continuous lifecycle monitoring, but most medtech manufacturers lack the systems and internal alignment to keep up, said speakers at the Veeva MedTech Summit.
Medtech Insight - November 16, 2026
The Insight Room: Separating AI Innovation From Theater at the Point of Care
The episode discusses how to tell real innovation from theater, what is actually proprietary in a pharma-specific AI model, and how point-of-care signals turn into recommendations.
Medtech Insight - November 16, 2026
The episode discusses how to tell real innovation from theater, what is actually proprietary in a pharma-specific AI model, and how point-of-care signals turn into recommendations.
Medtech Insight - November 16, 2026
Execs On The Move: November 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 16, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 16, 2026
US Proposal Allowing NAC Use In Supplements Frames Door Through ‘Preclusion Clause’ For More
Proposed rule notes regulatory emphasis on protecting incentives for new drug development but suggests FDA could consider requests for exceptions to prohibition on using in supplements ingredients previously studied or approved for use as drugs.
HBW Insight - November 17, 2026
Proposed rule notes regulatory emphasis on protecting incentives for new drug development but suggests FDA could consider requests for exceptions to prohibition on using in supplements ingredients previously studied or approved for use as drugs.
HBW Insight - November 17, 2026
New Growth Frontier: Formycon Reveals Tezspire And Hemlibra Niche-Buster Biosimilars
As Formycon names two niche-buster biosimilar targets, it faces a Q4 uphill to generate €20m to reach the low-end of 2026 revenue guidance, after lowering its adjusted EBITDA range.
Generics Bulletin - November 16, 2026
As Formycon names two niche-buster biosimilar targets, it faces a Q4 uphill to generate €20m to reach the low-end of 2026 revenue guidance, after lowering its adjusted EBITDA range.
Generics Bulletin - November 16, 2026
Biocon Gets FDA Approval For Perjeta Biosimilar, But What Is The US Market Worth?
Biocon has received FDA approval for its biosimilar to Roche/Genentech’s Perjeta and has claimed the earliest licensed launch dates for its Pebrilzo, but what is the US pertuzumab market size it could tap?
Generics Bulletin - November 16, 2026
Biocon has received FDA approval for its biosimilar to Roche/Genentech’s Perjeta and has claimed the earliest licensed launch dates for its Pebrilzo, but what is the US pertuzumab market size it could tap?
Generics Bulletin - November 16, 2026
Sandoz Seeks To Gain Aflibercept Foothold In US With Private-Label Deal
As it announced the launch of its Enzeevu aflibercept rival to Eylea earlier today, Sandoz said it believed its newly-revealed private-label deal for the biosimilar would “substantially expand” the product’s reach in the US, where multiple other versions of aflibercept are already available.
Generics Bulletin - November 16, 2026
As it announced the launch of its Enzeevu aflibercept rival to Eylea earlier today, Sandoz said it believed its newly-revealed private-label deal for the biosimilar would “substantially expand” the product’s reach in the US, where multiple other versions of aflibercept are already available.
Generics Bulletin - November 16, 2026
Aspen Prepares For Generic Semaglutide Launches In Upcoming Months
Aspen has won generic semaglutide approvals in Brazil and South Africa, planning launches in coming months in markets where rivals have already launched or hold approvals.
Generics Bulletin - November 16, 2026
Aspen has won generic semaglutide approvals in Brazil and South Africa, planning launches in coming months in markets where rivals have already launched or hold approvals.
Generics Bulletin - November 16, 2026
Biopharma Financial Conditions On The Right Track After A Valuation Reset
Biopharma fundraising has been up in 2026, although valuations reset in recent months, perhaps cooling the financial markets to a healthier level of investment focused on high-quality companies with clinical-stage drug candidates as investors look to 2027.
In Vivo - November 16, 2026
Biopharma fundraising has been up in 2026, although valuations reset in recent months, perhaps cooling the financial markets to a healthier level of investment focused on high-quality companies with clinical-stage drug candidates as investors look to 2027.
In Vivo - November 16, 2026
From Target Lists to Trial Readouts: What’s Next for AI in Longevity Research
From Microsoft’s agentic discovery tools to Novartis and BioAge’s decades-long cohorts, AI is speeding target identification in aging, while trial endpoints and clinical proof remain the unresolved constraints.
In Vivo - November 16, 2026
From Microsoft’s agentic discovery tools to Novartis and BioAge’s decades-long cohorts, AI is speeding target identification in aging, while trial endpoints and clinical proof remain the unresolved constraints.
In Vivo - November 16, 2026




